First Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Diagnostic Imaging Product in the United States

San Francisco, CA (UroToday.com) — Telix Pharmaceuticals Limited announces that the first patients have been dosed in the Phase III ZIRCON¹ (NCT03849118) clinical trial of Telix’s renal cancer diagnostic imaging product TLX250-CDx (89Zr-girentuximab) in the United States.